References
- Verstovsek S, Golemovic M, Kantarjian H, Manshouri T, Estrov Z, Manley P, et al. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer 2005; 104: 1230–1236
- Chow K U, Nowak D, Hofmann W, Schneider B, Hofmann W K. Imatinib induces apoptosis in CLL lymphocytes with high expression of Par-4. Leukemia 2005; 19: 1103–1105
- Boehrer S, Nowak D, Hochmuth S, Kim S Z, Trepohl B, Afkir A, et al. Daxx overexpression in T-lymphoblastic Jurkat cells enhances caspase-dependent death receptor and drug-induced apoptosis in distinct ways. Cell Signal 2005; 17: 581–595
- Chow K U, Nowak D, Boehrer S, Ruthardt M, Knau A, Hoelzer D, et al. Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. Biochem Pharmacol 2003; 66: 711–724
- Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005; 9: 59–71
- Wendel H G, De Stanchina E, Fridman J S, Malina A, Ray S, Kogan S, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428: 332–337
- Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002; 2: 764–776
- Dang C V. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999; 19: 1–11
- Eilers M. Control of cell proliferation by Myc family genes. Mol Cells 1999; 9: 1–6
- Lysechko T L, Ostergaard H L. Differential Src family kinase activity requirements for CD3 zeta phosphorylation/ZAP70 recruitment and CD3 epsilon phosphorylation. J Immunol 2005; 174: 7807–7814
- Huntington N D, Tarlinton D M. CD45: direct and indirect government of immune regulation. Immunol Lett 2004; 94: 167–174
- Wange R L. TCR signaling: another Abl-bodied kinase joins the cascade. Curr Biol 2004; 14: R562–R564
- Byrd J C, Stilgenbauer S, Flinn I W. Chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2004; 163–183
- O'Hare T, Walters D K, Stoffregen E P, Jia T, Manley P W, Mestan J, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 4500–4505
- Mateyak M K, Obaya A J, Sedivy J M. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol 1999; 19: 4672–4683
- Furstoss O, Manes G, Roche S. Cyclin E and cyclin A are likely targets of Src for PDGF-induced DNA synthesis in fibroblasts. FEBS Lett 2002; 526: 82–86
- Riley D, Carragher N O, Frame M C, Wyke J A. The mechanism of cell cycle regulation by v-Src. Oncogene 2001; 20: 5941–5950
- Mamidipudi V, Zhang J, Lee K C, Cartwright C A. RACK1 regulates G1/S progression by suppressing Src kinase activity. Mol Cell Biol 2004; 24: 6788–6798
- Plattner R, Pendergast A M. Activation and signaling of the Abl tyrosine kinase: bidirectional link with phosphoinositide signaling. Cell Cycle 2003; 2: 273–274
- Plattner R, Koleske A J, Kazlauskas A, Pendergast A M. Bidirectional signaling links the Abelson kinases to the platelet-derived growth factor receptor. Mol Cell Biol 2004; 24: 2573–2583